Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Oncology
|
| gptkbp:anatomy |
pleomorphic cells
lipoblasts myxoid cells |
| gptkbp:associated_with |
fatigue
weight loss chromosomal translocation palliative care options psychosocial support needs increased risk of secondary cancers lymph node involvement painful mass vascular invasion pain management needs |
| gptkbp:characterized_by |
myxoid stroma
|
| gptkbp:clinical_trial |
ongoing
completed necrosis mitotic activity high cellularity myxoid change pleomorphic lipoblasts |
| gptkbp:death |
20-50% for metastatic
60-80% for localized |
| gptkbp:diagnosis |
gptkb:MRI
CT scan variable imaging studies biopsy |
| gptkbp:first_described_by |
1970s
|
| gptkbp:genetic_studies |
FUS-CHOP fusion gene
translocation t(12;16)(q13;p11) |
| https://www.w3.org/2000/01/rdf-schema#label |
myxoid liposarcoma
|
| gptkbp:is_a |
gptkb:Kaposi's_sarcoma
|
| gptkbp:is_common_in |
adults
|
| gptkbp:is_located_in |
thigh
trunk retroperitoneum |
| gptkbp:number_of_stages |
localized
metastatic |
| gptkbp:occurs_in |
muscle tissue
|
| gptkbp:patient_population |
more common in males
average age of diagnosis is 50s |
| gptkbp:related_to |
gptkb:dedifferentiated_liposarcoma
gptkb:pleomorphic_liposarcoma |
| gptkbp:research_areas |
biomarker discovery
clinical outcomes genetic profiling |
| gptkbp:research_focus |
molecular mechanisms
treatment strategies |
| gptkbp:risk_factor |
genetic predisposition
previous radiation exposure |
| gptkbp:symptoms |
pain
swelling |
| gptkbp:treatment |
gptkb:immunotherapy
gptkb:surgery radiation therapy chemotherapy targeted therapy adjuvant therapy neoadjuvant therapy recurrence possible response to chemotherapy varies surgical margins important for prognosis |
| gptkbp:bfsParent |
gptkb:Oncology
|
| gptkbp:bfsLayer |
4
|